CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 26.4% in March
by Scott Moore · The Cerbat GemCalciMedica Inc. (NASDAQ:CALC – Get Free Report) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totaling 337,917 shares, a decline of 26.4% from the March 15th total of 459,110 shares. Approximately 3.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 244,586 shares, the short-interest ratio is presently 1.4 days.
Wall Street Analysts Forecast Growth
CALC has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of CalciMedica to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. Oppenheimer reduced their target price on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, March 5th. Finally, HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research report on Thursday, January 29th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, CalciMedica has an average rating of “Hold” and an average price target of $13.00.
Check Out Our Latest Analysis on CALC
CalciMedica Price Performance
Shares of CALC stock traded up $0.01 during trading hours on Wednesday, reaching $0.63. 119,567 shares of the company were exchanged, compared to its average volume of 1,109,260. CalciMedica has a fifty-two week low of $0.46 and a fifty-two week high of $7.20. The stock’s fifty day moving average is $0.64 and its two-hundred day moving average is $2.88. The company has a market cap of $9.95 million, a price-to-earnings ratio of -0.32 and a beta of 0.76.
CalciMedica (NASDAQ:CALC – Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter. On average, research analysts anticipate that CalciMedica will post -2.21 earnings per share for the current year.
Institutional Trading of CalciMedica
Several institutional investors and hedge funds have recently made changes to their positions in the business. Cetera Investment Advisers raised its position in shares of CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares during the last quarter. Meritage Portfolio Management raised its position in shares of CalciMedica by 33.8% during the 3rd quarter. Meritage Portfolio Management now owns 61,539 shares of the company’s stock valued at $189,000 after acquiring an additional 15,539 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of CalciMedica by 26.1% during the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after acquiring an additional 18,300 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of CalciMedica during the 4th quarter valued at $127,000. Finally, Envestnet Asset Management Inc. increased its stake in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares in the last quarter.
About CalciMedica
CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.
The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.